Cardiol Therapeutics
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. over the previous period. Total operating expenses were $29,537,149.
Profit Margin
| 2017 | 0 | -1.66M | |
|---|---|---|---|
| 2018 | 0 | -15.89M | |
| 2019 | 0 | -13.98M | |
| 2020 | 0 | -20.64M | |
| 2021 | 78.76K | -24.72M | -31391.46% |
| 2022 | 0 | -11.52M | |
| 2023 | 0 | -28.12M |
CRDL.TO Income Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Revenue | |||||||
Revenue | 0 | 0 | 78.76K | 0 | 0 | 0 | 0 |
Cost of revenue | 248.35K | 219.90K | 0 | 229.53K | 150.57K | 0 | 53.34K |
Gross profit | -248.35K | -219.90K | 78.76K | -229.53K | -150.57K | 0 | -53.34K |
Operating exp. | |||||||
Research and development | 14.22M | 18.96M | 10.87M | 10.51M | 3.53M | 1.53M | 441.25K |
Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 29.53M | 41.33M | 38.74M | 20.69M | 14.12M | 7.49M | 1.59M |
Operating income | -29.78M | -50.33M | -45.47M | -20.60M | -13.58M | -7.49M | -1.59M |
Other income (expenses), net | 1.65M | 19.40M | 13.83M | 49.52K | -100.47K | -7.83M | -65.49K |
Income before tax | -28.12M | -30.93M | -31.63M | -20.64M | -13.68M | -15.89M | -1.66M |
Income tax expense | 1 | -19.40M | -6.91M | 7.39K | 299.41K | -7.73M | 60.56K |
Net income | -28.12M | -11.52M | -24.72M | -20.64M | -13.98M | -15.89M | -1.66M |
Earnings per share | |||||||
Basic EPS | -0.44 | -0.18 | -0.57 | -0.69 | -0.54 | -1.03 | -0.07 |
Diluted EPS | -0.44 | -0.18 | -0.57 | -0.69 | -0.54 | -1.03 | -0.07 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |